Genetic Technologies Stock News

Genetic Technologies Ltd. - ADR (GENE) shares closed 1.6% lower than its previous 52 week low, giving the company a market cap of $28M. The stock is currently flat year-to-date, down 54.1% over the past 12 months, and down 58.8% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 60.1% lower than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -100.0% The company's stock price performance over the past 12 months lags the peer average by -3976.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Genetic Technologies Ltd. - ADR (GENE) shares closed today at 1.6% above its 52 week low of $1.85, giving the company a market cap of $29M. The stock is currently up 0.5% year-to-date, down 50.3% over the past 12 months, and down 59.3% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.7%. Trading Activity Trading volume this week was 47.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 2.6% lower than its 5-day moving average, 6.5% lower than its 20-day moving average, and 30.6% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -106.9% The company's stock price performance over the past 12 months lags the peer average by -1009.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Genetic Technologies Ltd. - ADR (GENE) shares closed today at 0.5% above its 52 week low of $1.87, giving the company a market cap of $29M. The stock is currently down 46.8% year-to-date, down 43.8% over the past 12 months, and down 55.7% over the past five years. This week, the Dow Jones Industrial Average rose 2.1%, and the S&P 500 rose 2.1%. Trading Activity Trading volume this week was 25.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -318.6% The company's stock price performance over the past 12 months lags the peer average by -290.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Genetic Technologies Ltd. - ADR (GENE) shares closed 0.8% lower than its previous 52 week low, giving the company a market cap of $30M. The stock is currently down 45.6% year-to-date, down 43.8% over the past 12 months, and down 54.6% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 26.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -312.3% The company's stock price performance over the past 12 months lags the peer average by -300.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

MELBOURNE, Australia, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness

MELBOURNE, Australia, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness

Study to focus on women of African American descent for expanded polygenic risk test Study to focus on women of African American descent for expanded polygenic risk test

Applied Genetic Technologies Corporation (AGTC) CEO Sue Washer on Q4 2021 Results - Earnings Call Transcript

Company to present at H.C. Wainwright 23rd Annual Global Investment Conference taking place virtually September 13-15, 2021 Company to present at H.C. Wainwright 23rd Annual Global Investment Conferen

MELBOURNE, Australia, July 26, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, “Company”, “GTG”), a global leader in Genomics based tests in health, wellness and serious d

Genetic Technologies Limited (NASDAQ: GENE) has agreed to acquire EasyDNA's brand and distribution rights from BelHealth for $4 million in cash and stock. EasyDNA currently sells paternity, oncolog

MELBOURNE, Australia, July 09, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG, NASDAQ: GENE, "Company", "GTG"), a diversified Genomics and AI driven preventative health business, tod

MELBOURNE, Australia, June 11, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a diversified Genomics and AI driven preventative health busine

MELBOURNE, Australia, May 13, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a diversified Genomics and AI driven preventative health busines